VPB0130 - Alterations in the coagulation profile and mortality due to covid-19 during the first and second wave in peruvians: A retrospective cohort in a national reference center.

Sunday, July 10, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: Virtual

Presenting Author(s)

Rafael Pichardo-Rodriguez, MD

Clinical Research
Ricardo Palma University, Lima-Peru.
Lima, Lima, Peru

Co-Author(s)

WP

Willy Peña-Oscuvilca

Clinical Research
Clinical Research Institute “Fausto Garmendia Lorena". National University "Mayor de San Marcos", Lima-Peru.
Lima, Lima, Peru
Lc

Liz cordova-Cueva

Clinical Research
Nephrology Service. National Hospital "Dos de Mayo", Lima-Peru
Lima, Lima, Peru
JD

JHONY A. DE LA CRUZ-VARGAS

Clinical Research
Research Institute in Biomedical Sciences (INICIB). Ricardo Palma University, Lima-Peru.
Lima, Lima, Peru
OR

Oscar Ruiz-Franco

Clinical Research
Clinical Research Institute “Fausto Garmendia Lorena". National University "Mayor de San Marcos", Lima-Peru.
Lima, Lima, Peru
FG

Fausto Garmendia-Lorena

Clinical Research
Clinical Research Institute “Fausto Garmendia Lorena". National University "Mayor de San Marcos", Lima-Peru.
Lima, Lima, Peru

Background: Changes in the coagulation profile have been associated with adverse clinical outcomes in patients with COVID-19. It is relevant to evaluate the changes in the coagulation profile and its impact on mortality from COVID-19 during the first and second waves in Peru.

Aims: To evaluate the alterations and impact of the coagulation profile on mortality from COVID-19 during the first and second waves in Peruvians.

Methods: Retrospective cohort carried out at the "Dos de Mayo" National Hospital, Lima-Peru during the years 2020 and 2021. Peruvians over 18 years of age were included, excluding those with congenital hemostasis disorders, pneumonia caused by other agents and chronic users of anticoagulants. SARS-COV2 pneumonia was defined as infiltrate in lung TEM + positive RT-PCR. Alterations in coagulation parameters were determined by prolonged prothrombin time (PT>14s) and/or prolonged activated thromboplastin time (APTT>35s) and/or fibrinogen < 200 mg/dL and/or fibrinogen >400 mg/dL. dL. The sample was consecutive, reaching a sample of 300 patients from the first and 300 from the second wave. Data was collected and entered into a database and sent for analysis after quality control. Were presented summary measures for the qualitative and quantitative variables. A logistic regression equation was modeled to estimate the adjusted OR of the different coagulation parameters altered. The data were processed RStudio version 1.3.1093.

Results: A total of 600 patients were included. Male was the most frequent sex during the two periods. Figure 1 shows the baseline characteristics. Fibrinogen < 200mg/dL during the first wave was associated with a lower risk of death (OR: 0.07; 95%-CI: 0.01, 0.90). Table 2 shows the results of the multivariate analysis.

Conclusion(s): Apparently the changes in the coagulation profile caused by COVID-19 in Peruvians during the first and second waves were not associated with higher mortality. Low fibrinogen seemed to offer protection during the first wave.